Major bleeding · people with antiphospholipid antibodies and no history of thrombosis
1 finding from 1 review
Minor bleeding · people with antiphospholipid antibodies and no history of thrombosis
ASA showed no clear difference in bleeding ‐ minor compared with placebo (low certainty).
1 finding from 1 review
Rate of amputation · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ulcer healing · patients with Buerger's disease
1 finding from 1 review
Pain Measured using a validated pain score or scale, or quality of life questionnaire · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects Local or systemic inflammatory response, cardiovascular abnormalities, and thromboembolic complications · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
30‐Day amputation‐free survival · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain‐free walking distance · patients with Buerger's disease
1 finding from 1 review
Intervention not reported
Pain‐free walking distance (m) · adults with intermittent claudication
1 finding from 1 review
Intervention not reported
Maximum walking distance (m) · adults with intermittent claudication
1 finding from 1 review
Intervention not reported
Ankle brachial index · adults with intermittent claudication
1 finding from 1 review
Intervention not reported
Mortality: all‐cause deaths · adults with intermittent claudication
The intervention showed no clear difference in mortality: all‐cause deaths (moderate certainty).
1 finding from 1 review
Intervention not reported
Amputation · adults with intermittent claudication
The intervention showed no clear difference in amputation (low certainty).
1 finding from 1 review
Intervention not reported
Quality of Life SF‐36 Physical Summary score (scale 0 to 100, higher score indicates better quality of life) · adults with intermittent claudication
1 finding from 1 review
Intervention not reported
Quality of Life SF‐36 Mental Summary score (scale 0 to 100, higher score indicates better quality of life) · adults with intermittent claudication
1 finding from 1 review
Incidence of recurrent VTE1 after initial treatment (up to 15 days) · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 after initial treatment (up to 15 days) compared with UFH (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with venous thromboembolism.
LMWH probably leads to lower incidence of recurrent VTE1 (3 months compared with UFH (moderate certainty).
2 findings from 1 review
Reduction in thrombus size (pre‐ and post‐treatment venograms) · patients with venous thromboembolism.
LMWH may leads to lower reduction in thrombus size (pre‐ and post‐treatment venograms) compared with UFH (low certainty).
1 finding from 1 review
Major bleeding · patients with venous thromboembolism.
LMWH probably leads to lower incidence of major haemorrhagic episodes (during initial treatment ‐… compared with UFH (moderate certainty).
1 finding from 1 review
Overall mortality (end of · patients with venous thromboembolism.
LMWH showed no clear difference in overall mortality (end of compared with UFH (moderate certainty).
1 finding from 1 review